It has been reported that there was a long-lasting significant decrease not only of γδT cells, but also of total WBC, lymphocytes, CD4+ T cells, and eosinophils 1 year after the first infusion of zoledronic acid.
3.5. Effects of ZOL on anti-cancer immunity. In addition to its effects on bone cells, ZOL has profound effects on the immune system, including a plethora of immune cell subsets expressing the mevalonate pathway enzymes, leading to a general increase in anti-tumour immunity [65].
Bisphosphonates are well tolerated with chronic administration and have very few adverse effects. Research suggests that these medications can stimulate the immune system.
Zoledronic acid is in a class of medications called bisphosphonates. It works by slowing bone breakdown, increasing bone density (thickness), and decreasing the amount of calcium released from the bones into the blood.
According to a list of zoledronic acid side-effects, dangerous side-effects such as coma, confusion, convulsions, difficult breathing, hypotension, atrial fibrillation, and cardiac arrhythmia secondary to hypocalcemia are possible [16].
User Reviews for Zoledronic acid to treat Prevention of Osteoporosis. Zoledronic acid has an average rating of 4.4 out of 10 from a total of 42 ratings for the treatment of Prevention of Osteoporosis. 31% of reviewers reported a positive experience, while 55% reported a negative experience.
Zoledronic acid medication is a long-acting drug. As such, it stays in your body longer than 12 months (probably more than 24 months). Therefore, delaying your treatment for a number of months will not put you at a higher risk of sustaining fragility fracture nor cause significant decline in your bone mineral density.
Zoledronic acid can cause flu-like symptoms such as joint and muscle pain, fatigue, shivering and fever. These can last for a few days. Your treatment team can advise you about taking mild pain relief to help.
Discontinuation of therapy should be considered by doctors after 3 to 5 years in patients with osteoporosis at low risk of fracture. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.
You should not be treated with zoledronic acid if you are allergic to it. You also should not receive Reclast if you have: low levels of calcium in your blood (hypocalcemia); or. severe kidney disease.
Official answer. Yes, Prolia (denosumab) does appear to weaken your immune system. Research has shown people who take Prolia are at an increased risk of serious infections leading to hospitalizations, including serious infections of the skin, abdominal, urinary tract, and ear.
Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res.
Long-term bisphosphonate therapy has been linked to a rare type of thigh fracture. This injury, known as atypical femoral fracture, is similar to a stress fracture, causing pain that begins subtly and can gradually worsen. If not identified early on, a complete fracture of the thighbone can occur.
In one comparative study of zoledronic acid and denosumab, denosumab showed a greater increase in spinal bone mass density (BMD) compared to zoledronic acid. Zoledronic acid also showed a greater incidence of flu-like symptoms. Based on this study, Prolia may be more effective for certain people.
Tell your doctor right away if you have agitation, blood in the urine, confusion, decreased urine output, depression, dizziness, headache, irritability, lethargy, muscle twitching, nausea, rapid weight gain, seizures, stupor, swelling of the face, ankles, or hands, or unusual tiredness or weakness.
The usual dose is 5 mg given as one infusion per year into a vein by your doctor or nurse. The infusion will take at least 15 minutes. In case you recently broke your hip, it is recommended that Zoledronic acid 5 mg is administered two or more weeks after your hip repair surgery.
The results of this trial indicate that a once-yearly infusion of zoledronic acid during a 3-year period significantly reduces the risk of vertebral, hip, and other fractures in patients with postmenopausal osteoporosis.
Zoledronate (zoledronic acid) Zoledronate is an osteoporosis medication that can help strengthen your bones and reduce your risk of breaking a bone. It is available as an annual intravenous infusion (drip). Zoledronate is a 'bisphosphonate' – a group of drugs that work by slowing down the cells that break down bone.
Check with your doctor or pharmacist before you start or stop taking any other drugs. The drinking of alcohol (in small amounts) does not appear to affect the safety or usefulness of zoledronic acid. pregnancy. It is best to use birth control while being treated with zoledronic acid.
Hair loss can occur with Zometa use. Hair loss can also occur with cancer treatments that you may have with Zometa. These treatments include chemotherapy or radiation therapy.
Abstract. Zoledronic acid is effective for osteoporosis at a single annual intravenous dose. It usually causes few adverse effects; the most common are related to acute phase reactions. We reported the case of a 64-year-old woman who presented flare-up of hand osteoarthritis after zoledronic acid infusions.
CONSIDERED A HAZARDOUS SUBSTANCE ACCORDING TO OSHA 29 CFR 1910.1200. Possible risk of impaired fertility. Possible risk of harm to the unborn child. Harmful: danger of serious damage to health by prolonged exposure through inhalation.
One death (from any cause) is prevented for every 27 patients who received zoledronic acid instead of placebo (NNT = 27; 95% CI, 15.4 to 96.3).
Administration of Zoledronic Acid Injection 4 mg given as a 5-minute intravenous infusion has been shown to result in an increased risk of renal toxicity, as measured by increases in serum creatinine, which can progress to renal failure.